ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia : A report from the acute leukemia working party of the EBMT

Show full item record



Permalink

http://hdl.handle.net/10138/206989

Citation

Canaani , J , Savani , B N , Labopin , M , Michallet , M , Craddock , C , Socie , G , Volin , L , Maertens , J A , Crawley , C , Blaise , D , Ljungman , P T , Cornelissen , J , Russell , N , Baron , F , Gorin , N , Esteve , J , Ciceri , F , Schmid , C , Giebel , S , Mohty , M & Nagler , A 2017 , ' ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia : A report from the acute leukemia working party of the EBMT ' , American Journal of Hematology , vol. 92 , no. 8 , pp. 789-796 . https://doi.org/10.1002/ajh.24771

Title: ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia : A report from the acute leukemia working party of the EBMT
Author: Canaani, Jonathan; Savani, Bipin N.; Labopin, Myriam; Michallet, Mauricette; Craddock, Charles; Socie, Gerard; Volin, Liisa; Maertens, Johan A.; Crawley, Charles; Blaise, Didier; Ljungman, Per T.; Cornelissen, Jan; Russell, Nigel; Baron, Frederic; Gorin, Norbert; Esteve, Jordi; Ciceri, Fabio; Schmid, Christoph; Giebel, Sebastian; Mohty, Mohamad; Nagler, Arnon
Contributor: University of Helsinki, Clinicum
Date: 2017-08
Language: eng
Number of pages: 8
Belongs to series: American Journal of Hematology
ISSN: 0361-8609
URI: http://hdl.handle.net/10138/206989
Abstract: ABO incompatibility is commonly observed in stem cell transplantation and its impact in this setting has been extensively investigated. HLA-mismatched unrelated donors (MMURD) are often used as an alternative stem cell source but are associated with increased transplant related complications. Whether ABO incompatibility affects outcome in MMURD transplantation for acute myeloid leukemia (AML) patients is unknown. We evaluated 1,013 AML patients who underwent MMURD transplantation between 2005 and 2014. Engraftment rates were comparable between ABO matched and mismatched patients, as were relapse incidence [34%; 95% confidence interval (CI), 28-39; for ABO matched vs. 36%; 95% CI, 32-40; for ABO mismatched; P=.32], and nonrelapse mortality (28%; 95% CI, 23-33; for ABO matched vs. 25%; 95% CI, 21-29; for ABO mismatched; P=.2). Three year survival was 40% for ABO matched and 43% for ABO mismatched patients (P=.35), Leukemia free survival rates were also comparable between groups (37%; 95% CI, 32-43; for ABO matched vs. 38%; 95% CI, 33-42; for ABO mismatched; P=.87). Incidence of grade II-IV acute graft versus host disease was marginally lower in patients with major ABO mismatching (Hazard ratio of 0.7, 95% CI, 0.5-1; P=.049]. ABO incompatibility probably has no significant clinical implications in MMURD transplantation.
Subject: BONE-MARROW-TRANSPLANTATION
CORD BLOOD TRANSPLANTATION
VERSUS-HOST-DISEASE
HEMATOLOGIC MALIGNANCIES
RISK-FACTORS
IMPACT
OUTCOMES
COMPATIBILITY
RECIPIENTS
MORTALITY
3121 Internal medicine
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Canaani_et_al_2 ... ournal_of_Hematology_1.pdf 690.7Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record